Episode #104| 3DHEALS2026 JP Morgan San Francisco (Live Recording) - Invest in 3D

A crowded JP Morgan week can blur into noise, so we built a quieter stage to focus on what actually moves healthcare forward: 3D software‑planned care, on‑demand manufacturing, and proof that patients and payers can feel. Recorded live in San Francisco, this special episode brings founders and investors together to show how 3D data and advanced manufacturing are turning personalization into a scalable, measurable reality.We start with a rare blueprint for value in spine surgery: virtual planning, patient‑specific 3D printed implants, and post‑op analytics that cut two‑year reoperations by 74% while compressing lead times from eight weeks to eight days. From there, the conversation widens fast. Hear how microarray patches with five‑micron precision enable co‑delivery without co‑formulation and factory‑level scale; how therapeutic hardware draws on bone biology to reduce revisions; how personalized pessaries bring dental‑style business models to women’s health; and how drill‑free, patient‑specific dental implants fit in six days without a single turn of a drill.We also explore the frontier where human recovery meets robotics. A single bionic hand platform serves amputees and humanoid robots, translating human manipulation data into industrial automation while staying Medicare‑covered. On the R&D side, vascularized tissues and cryobioprinted models aim to fix translational failure by making complex biology reproducible and shippable. Structural biopolymer fibers unlock sutures, meshes, and sports medicine implants with clean‑room scale. A countertop system automates cell therapy final formulation so community hospitals can treat more patients safely. And a new biomanufacturing approach targets IVIG supply constraints by achieving human‑like B‑cell densities in ultrafast 3D printed bioreactors. We close with high‑viscosity inkjet that prints materials traditional jets can’t, powering durable dental parts and microneedle patches at true production speeds.Along the way, an investor panel compares notes on 2026: where exits might return, where non‑dilutive capital is shifting, and what it now takes to earn a check—clear end‑user value, defensible tech, and a distribution edge. If you care about medtech, bioprinting, cell and gene therapy delivery, or the future of personalized care, this is your field guide to what’s working right now.If this conversation sparks new ideas or a partnership you want to pursue, subscribe, share the episode with a colleague, and leave a quick review telling us which breakthrough you want to hear more about.Event speaker biographies: https://3dheals.com/life-in-3d-investing-in-the-next-frontier/On-Demand Video (Pending publication): https://3dheals.com/courses/Pitch 3D Application link: https://3dheals.com/pitch3d/Send us Fan MailSupport the showSubscribe to our premium version and support the show. Follow us: Twitter  Instagram Linkedin 3DHEALS WebsiteFacebookFacebook GroupYoutube channelAbout Pitch3D